{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T23:03:46Z","timestamp":1784070226219,"version":"3.55.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"15","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T00:00:00Z","timestamp":1721433600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007956","name":"Nanjing University of Chinese Medicine","doi-asserted-by":"publisher","award":["SEZYB2023004"],"award-info":[{"award-number":["SEZYB2023004"]}],"id":[{"id":"10.13039\/501100007956","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.heliyon.2024.e34969","type":"journal-article","created":{"date-parts":[[2024,7,21]],"date-time":"2024-07-21T10:43:37Z","timestamp":1721558617000},"page":"e34969","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Novel insights into post-marketing AEs associated with leuprorelin: A comprehensive analysis utilizing the FAERS database"],"prefix":"10.1016","volume":"10","author":[{"given":"Huawei","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinping","family":"Bu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinzhe","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningsheng","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiasong","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6959-8919","authenticated-orcid":false,"given":"Zhiwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.heliyon.2024.e34969_bib1","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1517\/13543784.16.11.1851","article-title":"Leuprolide acetate: a drug of diverse clinical applications","volume":"16","author":"Wilson","year":"2007","journal-title":"Expet Opin. Invest. Drugs"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e34969_bib2","first-page":"H454","article-title":"Gonadal hormones and pathogenesis of occlusive arterial thrombosis","volume":"234","author":"Uzunova","year":"1978","journal-title":"Am. J. Physiol."},{"issue":"Suppl 1","key":"10.1016\/j.heliyon.2024.e34969_bib3","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1007\/s00432-006-0133-5","article-title":"Antiandrogen treatments in locally advanced prostate cancer: are they all the same?","volume":"132","author":"Gillatt","year":"2006","journal-title":"J Cancer Res Clin"},{"issue":"12","key":"10.1016\/j.heliyon.2024.e34969_bib4","first-page":"937","article-title":"[GnRH-agonists in the therapy of endometriosis]","volume":"47","author":"Hoffmann","year":"1990","journal-title":"Ther. Umsch."},{"key":"10.1016\/j.heliyon.2024.e34969_bib5","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.cbi.2019.05.050","article-title":"Synergistic interactions of phytochemicals with antimicrobial agents: potential strategy to counteract drug resistance","volume":"308","author":"Ayaz","year":"2019","journal-title":"Chem. Biol. Interact."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e34969_bib6","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/S0015-0282(16)61022-1","article-title":"A randomized, placebo-controlled, double-blind study evaluating leuprolide acetate depot treatment before myomectomy","volume":"52","author":"Friedman","year":"1989","journal-title":"Fertil. Steril."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e34969_bib7","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0022-3476(89)80806-6","article-title":"Effects of leuprolide in the treatment of central precocious puberty","volume":"114","author":"Lee","year":"1989","journal-title":"J Pediatr-Us"},{"issue":"10305","key":"10.1016\/j.heliyon.2024.e34969_bib8","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(21)00950-8","article-title":"Prostate cancer","volume":"398","author":"Sandhu","year":"2021","journal-title":"Lancet (N. Am. Ed.)"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e34969_bib9","first-page":"1051","article-title":"Screening for prostate cancer","volume":"104","author":"Carlsson","year":"2020","journal-title":"Med. Clin."},{"issue":"13","key":"10.1016\/j.heliyon.2024.e34969_bib10","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1056\/NEJMra1810764","article-title":"Endometriosis","volume":"382","author":"Zondervan","year":"2020","journal-title":"New Engl J Med"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e34969_bib11","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1152\/physiol.00013.2021","article-title":"Uterine fibroids: hiding in plain sight","volume":"37","author":"Stewart","year":"2022","journal-title":"Physiology"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e34969_bib12","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/humupd\/7.3.292","article-title":"Pathogenesis and epidemiology of precocious puberty. Effects of exogenous oestrogens","volume":"7","author":"Partsch","year":"2001","journal-title":"Hum. Reprod. Update"},{"issue":"8","key":"10.1016\/j.heliyon.2024.e34969_bib13","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2165\/00002018-200427080-00010","article-title":"Using MedDRA: implications for risk management","volume":"27","author":"Brown","year":"2004","journal-title":"Drug Saf."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e34969_bib14","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidem DR S"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e34969_bib15","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidem Dr S"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e34969_bib16","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e34969_bib17","series-title":"Bayesian Data Mining in Large Frequency Tables, with an Application to the FDA Spontaneous Reporting System","author":"Dumouche","year":"1999"},{"issue":"10","key":"10.1016\/j.heliyon.2024.e34969_bib18","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/j.clinthera.2010.09.009","article-title":"Sterile abscess formation in response to two separate branded long-acting gonadotropin-releasing hormone agonists","volume":"32","author":"Miller","year":"2010","journal-title":"CLIN THER"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e34969_bib19","doi-asserted-by":"crossref","first-page":"E136","DOI":"10.1111\/j.1440-1754.2011.02083.x","article-title":"Sterile abscess formation associated with depot leuprorelin acetate therapy for central precocious puberty","volume":"48","author":"Johnson","year":"2012","journal-title":"J. Paediatr. Child Health"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e34969_bib20","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1272\/jnms.74.306","article-title":"Injection-site granulomas resulting from the administration of both leuprorelin acetate and goserelin acetate for the treatment of prostatic cancer","volume":"74","author":"Shiota","year":"2007","journal-title":"J. Nippon Med. Sch."},{"issue":"10 Pt 1","key":"10.1016\/j.heliyon.2024.e34969_bib21","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0151-9638(07)92536-3","article-title":"[Granuloma at the injection site of leuprorelin acetate: foreign body reaction to polylactic acid]","volume":"134","author":"Vieu","year":"2007","journal-title":"Ann Dermatol Vener"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e34969_bib22","doi-asserted-by":"crossref","first-page":"e752","DOI":"10.1542\/peds.2008-1783","article-title":"Consensus statement on the use of gonadotropin-releasing hormone analogs in children","volume":"123","author":"Carel","year":"2009","journal-title":"Pediatrics"},{"issue":"9","key":"10.1016\/j.heliyon.2024.e34969_bib23","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1210\/jc.2001-020243","article-title":"Treatment of central precocious puberty by subcutaneous injections of leuprorelin 3-month depot (11.25 mg)","volume":"87","author":"Carel","year":"2002","journal-title":"J Clin Endocr Metab"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e34969_bib24","doi-asserted-by":"crossref","first-page":"E136","DOI":"10.1111\/j.1440-1754.2011.02083.x","article-title":"Sterile abscess formation associated with depot leuprorelin acetate therapy for central precocious puberty","volume":"48","author":"Johnson","year":"2012","journal-title":"J. Paediatr. Child Health"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e34969_bib25","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0022-3476(95)70534-1","article-title":"Local reactions to luteinizing hormone releasing hormone analog therapy","volume":"126","author":"Tonini","year":"1995","journal-title":"J Pediatr-Us"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e34969_bib26","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/S0022-3476(05)81162-X","article-title":"Two-year results of treatment with depot leuprolide acetate for central precocious puberty","volume":"121","author":"Neely","year":"1992","journal-title":"J Pediatr-Us"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e34969_bib27","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1046\/j.1464-410X.2003.t01-1-04022.x","article-title":"Leuprorelin acetate granulomas: recurrent subcutaneous nodules mimicking metastatic deposits at injections sites","volume":"91","author":"Saxby","year":"2003","journal-title":"BJU Int."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e34969_bib28","first-page":"E92","article-title":"Case - leuprolide acetate-induced necrotic skin ulceration","volume":"17","author":"Ian","year":"2023","journal-title":"Cuaj-Can Urol Assoc"},{"issue":"10","key":"10.1016\/j.heliyon.2024.e34969_bib29","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/j.clinthera.2010.09.009","article-title":"Sterile abscess formation in response to two separate branded long-acting gonadotropin-releasing hormone agonists","volume":"32","author":"Miller","year":"2010","journal-title":"CLIN THER"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e34969_bib30","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.urology.2005.11.015","article-title":"Failure of gonadotropin-releasing hormone agonists with and without sterile abscess formation at depot sites: insight into mechanisms?","volume":"67","author":"Daskivich","year":"2006","journal-title":"Urology"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e34969_bib31","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jmig.2014.12.153","article-title":"Medical treatment of ureteral obstruction associated with ovarian remnants and\/or endometriosis: report of three cases and review of the literature","volume":"22","author":"Vilos","year":"2015","journal-title":"J. Minim. Invasive Gynecol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e34969_bib32","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1159\/000479187","article-title":"Efficacy and tolerability of leuprorelin acetate (eligard(R)) in daily practice in Germany: pooled data from 2 prospective, non-interventional studies with 3- or 6-month depot formulations in patients with advanced prostate cancer","volume":"100","author":"Ohlmann","year":"2018","journal-title":"Urol. Int."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e34969_bib33","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1080\/14737140.2022.2082947","article-title":"Advanced delivery of leuprorelin acetate for the treatment of prostatic cancer","volume":"22","author":"Merseburger","year":"2022","journal-title":"Expert Rev Anticanc"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e34969_bib34","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000056592","article-title":"Optimal starting time for flutamide to prevent disease flare in prostate cancer patients treated with a gonadotropin-releasing hormone agonist","volume":"66","author":"Tsushima","year":"2001","journal-title":"Urol. Int."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e34969_bib35","first-page":"1168","article-title":"Efficacy and safety of leuprorelin acetate 6-month depot in prostate cancer patients: a Phase III, randomized, open-label, parallel-group, comparative study in Japan","volume":"45","author":"Suzuki","year":"2015","journal-title":"Jpn. J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e34969_bib36","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.urology.2004.03.032","article-title":"Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study","volume":"64","author":"Sato","year":"2004","journal-title":"Urology"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e34969_bib37","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3349\/ymj.2014.55.2.310","article-title":"Is high-dose leuprorelin acetate effective and safe in asian men with prostate cancer? An open-label, non-comparative, multi-center clinical trial","volume":"55","author":"Lee","year":"2014","journal-title":"Yonsei Med. J."},{"issue":"20","key":"10.1016\/j.heliyon.2024.e34969_bib38","first-page":"3610","article-title":"Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501): important lessons for future trials","volume":"119","author":"Schweizer","year":"2013","journal-title":"Cancer-Am Cancer Soc"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024110006?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024110006?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T22:08:40Z","timestamp":1784066920000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024110006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":38,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S2405844024110006"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e34969","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel insights into post-marketing AEs associated with leuprorelin: A comprehensive analysis utilizing the FAERS database","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e34969","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e34969"}}